New diabetes pill DA-2811 aims to improve blood sugar control
NCT ID NCT07239440
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests an experimental drug, DA-2811, in 288 adults with type 2 diabetes whose blood sugar is not well controlled despite taking two other diabetes medications. Participants will receive either DA-2811 or a placebo added to their current treatment. The main goal is to see if DA-2811 lowers HbA1c, a key blood sugar measure, over the study period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DA-2811 (an experimental oral drug for diabetes)
What this could lead to
If successful, this could provide a new add-on treatment option to help people with type 2 diabetes better manage their blood sugar levels.
What could go wrong
This is an early Phase 2 trial, so the drug may not prove effective or safe. It is only tested in a specific group and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, South Korea
Contact Email: •••••@•••••